Overweight status is associated with extensive signs of microvascular dysfunction and cardiovascular risk by Patel, Sunni R. et al.
1Scientific RepoRts | 6:32282 | DOI: 10.1038/srep32282
www.nature.com/scientificreports
Overweight status is associated 
with extensive signs of 
microvascular dysfunction and 
cardiovascular risk
Sunni R. Patel1, Srikanth Bellary2, Said Karimzad1 & Doina Gherghel1
The aim of this present study was to investigate if overweight individuals exhibit signs of vascular 
dysfunction associated with a high risk for cardiovascular disease (CVD). One hundred lean and 100 
overweight participants were recruited for the present study. Retinal microvascular function was 
assessed using the Dynamic Retinal Vessel Analyser (DVA), and systemic macrovascular function 
by means of flow-mediated dilation (FMD). Investigations also included body composition, carotid 
intimal-media thickness (c-IMT), ambulatory blood pressure monitoring (BP), fasting plasma 
glucose, triglycerides (TG), cholesterol levels (HDL-C and LDL-C), and plasma von Willebrand factor 
(vWF). Overweight individuals presented with higher right and left c-IMT (p = 0.005 and p = 0.002, 
respectively), average 24-h BP values (all p < 0.001), plasma glucose (p = 0.008), TG (p = 0.003), 
TG: HDL-C ratio (p = 0.010), and vWF levels (p = 0.004). Moreover, overweight individuals showed 
lower retinal arterial microvascular dilation (p = 0.039) and baseline-corrected flicker (bFR) responses 
(p = 0.022), as well as, prolonged dilation reaction time (RT, p = 0.047). These observations emphasise 
the importance of vascular screening and consideration of preventive interventions to decrease vascular 
risk in all individuals with adiposity above normal range.
Excess adipose tissue induces several metabolic changes, including dyslipidaemia, elevated blood pressure (BP), 
oxidative stress, and increased inflammation, thereby, contributing towards macro- and micro-vascular endothe-
lial dysfunctions, increased arterial stiffness, and atherosclerosis1,2. These changes are traditionally associated with 
obesity and are not often reported in those with lower levels of adiposity that are classed as overweight. Indeed, it 
is usually presumed that the cardiovascular risk is not heightened in those with a body mass index (BMI) between 
25–29.9 kg/m2 3. Nevertheless, it is now thought that overweight individuals actually have an approximately 60% 
higher risk of cardiovascular disease (CVD) mortality when compared to age-matched lean controls4. Indeed, it 
has been demonstrated that even from early life, an increased BMI is associated, amonfg other changes, with low 
levels of nitric oxide (NO), the key contributor to normal vascular function5. Overweight children and young 
adults show evidence of macrovascular endothelial dysfunction and increased arterial stiffness6, which is revers-
ible by increasing NO bioavailability and reduction of abdominal visceral fat7. It seems, therefore, that any excess 
adiposity would result in a higher chance of future cardiovascular risk.
It is well known that vascular endothelial dysfunction represents an early marker of atherosclerosis and 
precedes the clinical manifestations of CVD8. In addition, endothelial dysfunction affects the microcircula-
tion much earlier than the macrocirculation in the course of vascular disease development9. This observation 
is extremely important. Due to the large total surface area of the microvessels, even an early activation of the 
endothelium at this level could have a large impact on bodily vascular health10. Consequently, detection of func-
tional abnormalities at the microvascular level could serve as a better predictor for future risk of disease than 
testing macrovasculature.
Dynamic retinal vessel analysis (DVA) represents a non-invasive technique that assesses retinal microvascu-
lar motions in response to flickering light and by using this technique a diminished microvascular function has 
already been demonstrated in obese individuals11. However, no such studies have been carried out in overweight 
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adults that are generally perceived as being at some risk for CVD but not at a level that would demand preventa-
tive care. Therefore, the aim of this study was to investigate micro- and macro-vascular function parameters and 
their relationship with established markers for future cardiovascular risk in otherwise healthy, overweight indi-
viduals compared to lean, age- and sex-matched controls.
Methods
Written informed consent was obtained from all participants and ethical approval was granted from the local 
(Aston University) and NHS ethical committees (COREC West Midlands, UK). This study was designed and 
conducted in accordance with the tenets of the Declaration of Helsinki.
Study Population. The study population consisted of healthy, normotensive White-European participants 
aged 30–55 years that were screened and recruited from the Health Clinics at Aston University, Birmingham, UK. 
Weight classifications were determined according to WHO definitions, whereby normal weight was classed as a 
BMI of 18.5–24.9 kg/m2 and overweight as a BMI of 25–29.9 kg/m2.
Subjects were excluded if they were classified as obese (BMI > 30 kg/m2), as well as, if they had a positive diag-
nosis of, or were taking medication for, cardio- or cerebro-vascular disease, coronary artery disease, heart fail-
ure, arrhythmia, stroke, transient ischaemic attacks, peripheral vascular disease, diabetes, hypertension or severe 
dyslipidaemia (defined as plasma TG > 6.00 mmol/L or cholesterol levels > 7.00 mmol/L). Smokers (including 
previous history of smoking) and all subjects taking vasoactive substances including dietary/vitamin/anti-oxidant 
supplementation, bronchodilators were also excluded from the present study. In addition, a standard 75 g oral 
glucose tolerance test (OGTT) was performed according to the WHO protocols on all participants a week prior 
to all other measurements and only normoglycaemic participants were asked to return for subsequent tests.
Furthermore, subjects were excluded if they had a refractive error of more than ± 3 Dioptre Spherical (DS – 
depicting the convergent or divergent refractive power of the eye, i.e. hyperopia or myopia) and more than ± 1 
Dioptre Cylindrical (DC – depicts the degree of astigmatism, i.e. the curvature of the cornea and or lens of the 
eye) equivalent to minimise magnification error brought on by high refractive errors, and intraocular pressure 
(IOP) higher than 24 mmHg, cataract or any other media opacities, as well as, if they had a history of intraocular 
surgery or any form of retinal or neuro-ophthalmic disease affecting the ocular vascular system.
According to an already established procedure, when examining endothelial function, female participants 
were asked to fill in a validated menstrual cycle questionnaire and their investigations were carried out during the 
first week of the menstrual cycle (follicular phase)12.
Investigations. All participants were screened for cardiovascular disease by a physician. Prior to the date of 
the study, participants were asked to fast and refrain from caffeine, alcohol, chocolate, and carbonated drinks, and 
to not exercise for 12 hours before the measurements were taken.
General measurements. Anthropometric measures including height and weight were recorded using 
standard procedures. Body composition was measured using bioelectrical impedance (Biostat 220, Biospace, 
UK) to determine BMI, percentage body fat (PBF), waist-to-hip ratio (WHR), total fat mass, and fat free mass.
Blood sampling and analyses. A qualified phlebotomist carried out the blood sampling, and all sam-
ples were obtained during the morning of the study, between 9:00 and 10:00 AM. Fasting plasma glucose, TG, 
total and HDL-C were measured using standard routine laboratory techniques using the Reflotron Desktop 
Analyser (Roche Diagnostics, UK). The TG/HDL cholesterol ratio13 and Total/HDL cholesterol ratio alongside 
Framingham score as a means of cardiovascular risk were also determined from the above values14.
Laboratory-validated protocols15 for in-house ELISA-testing were adopted to carry out plasma sampling of 
von-Willebrand Factor (vWF) to investigate possible signs of endothelial damage in overweight individuals.
Micro- and macro-vascular studies. Ambulatory Blood Pressure. Ambulatory BP was measured using a 
24-hour computer-operated ambulatory BP and electrocardiography (ECG) monitor (Cardiotens-01, Meditech 
Ltd., Hungary) for each subject. Measurements were performed in ambulatory conditions and programmed to 
measure BP oscillometrically every 15 minutes during the subject’s active period and every 30 minutes during the 
passive period. The 24-hour data was later downloaded and systolic BP (SBP), diastolic BP (DBP) and mean BP 
[MBP ≈ (⅔ X DBP) + (⅓ X SBP)], were calculated using the Medibase software (Meditech Version 1.42).
Intima-media thickness. Real-time intima-media thickness measurements for both carotid arteries were 
obtained for all participants through analysis of ultrasound images taken from the right and left common carotid 
arteries at the neck using a high-resolution B-mode ultrasound system (Acuson Sequoia, 5 MHz linear trans-
ducer, Siemens, USA) according to an already published protocol16.
Retinal vascular function. Retinal vessel reactivity was measured with the dynamic retinal vessel analyser (DVA, 
IMEDOS GmbH, Jena, Germany) using an already established and recommended protocol17. All measure-
ments were performed in one randomly selected eye for each subject between 8:00 and 11:00 AM, and in a quiet, 
temperature-controlled room (22 °C)17,18. Retinal vessel reactivity, in the form of arterial and venous reaction 
time (RT) and maximum diameter (MD), were determined using our newly defined method of Sequential and 
Diameter Response Analysis (SDRA), which is described elsewhere19.
The following retinal vessel reactivity and time course parameters (using one-second averaged data for 3 
flicker cycles) were calculated (Fig. 1): baseline-diameter fluctuation (BDF), as the difference between maxi-
mum and minimum baseline vessel diameter; the maximum diameter (MD), as the maximal vessel dilation in 
response to flicker light stimulation expressed as a percentage from baseline; the MD reaction time (MDRT), 
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as the time taken (seconds) to reach the maximum vessel diameter during the 20-second flicker exposure; the 
maximum constriction (MC), as the percentage to baseline minimal vessel diameter within 30 seconds of the 
recovery period; and the maximum constriction reaction time (MCRT), as the time taken (seconds) to reach 
maximal vessel constriction. In addition, the dilation amplitude (DA), as the difference between maximal dilation 
and constriction responses, and the baseline-corrected flicker response (bFR), which accounted for the BDF were 
also determined19.
Brachial artery Flow Mediated Dilation (FMD). Brachial artery flow-mediated dilation (FMD) was measured 
using high-resolution ultrasonography, with a 7 mm 8 MHz linear-array (Siemens; Acuson Sequoia, UK). Briefly, 
vessel diameter was continuously measured, from the anterior to the posterior interface between the media and 
adventitia, using specialised wall-detection and artificial neural networking software (VIA® Software, UK), and 
the data was recorded on a personal computer. The procedure was carried out according to a previously validated 
and universally accepted protocol comprising of a 2-minute baseline recording, followed by 5 minutes of occlu-
sion, and a 2-minute recovery period. Following a subsequent 10-minute re-acclimatisation period, an exogenous 
NO donor (300 mcg sublingual glyceryl trinitrate – GTN tablet) was administered. The FMD% was determined as 
absolute change from baseline using real-time raw data, as well as, GTN-induced changes20.
Numerous factors have been known to contribute to the variability of FMD, mainly equipment- and 
operator-related, as well as, physiological influences. To minimise equipment- and operator-related influences, a 
standardised protocol was adhered to, and all analyses were performed off-line by a blinded observer. To mini-
mise physiological influences known to exert profound effects on endothelial function, i.e., diurnal variation and 
dietary substances, we further standardised environmental factors (temperature, noise, and excluded the use of 
vasoactive substances.
Statistical analysis. All analyses were performed using Statistica® software (StatSoft Inc.; Version 9, USA). 
Prior to any analysis, all data was tested for normal distribution and thus a suitable test was adopted. Differences 
in mean values for each of the measured biochemical, demographic, and anthropometric variables were com-
pared by independent samples t-test for continuous variables. A multivariate analysis was performed to test the 
influence of BMI, BP, and circulating markers on the measured variables. Comparison of retinal vessel reactiv-
ity for each of the 3 repeated flicker periods was made by Friedman analysis of variance (ANOVA) following 
within-group analysis as the data was not normally distributed even following log transformation. Differences 
in brachial artery and FMD responses (also not normally distributed) were assessed by Kruskal-Wallis testing. 
Differences between groups in retinal and systemic vascular function were computed by analysis of variance 
(ANOVA) or covariance (ANCOVA) where appropriate. A p value of < 0.05 was considered statistically signif-
icant for the retinal and brachial parameters, and a stricter criteria was adopted for within-group and multiple 
comparisons of the biochemical and demographic variables (p ≤ 0.01 to account for multiple comparisons and 
thereby minimise bias towards Type II errors).
Results
In the present study, an initial 226 individuals were screened for inclusion, following which 26 were excluded as 
they were diagnosed with impaired glucose tolerance and referred back to appropriate outpatient management. 
A final 200 subjects were recruited, based on the diagnosis criteria, and allocated to either the normal (n = 100; 
men = 48, women = 52) or overweight (n = 100; men = 51, women = 49) group. As evident in Table 1, there were 
Figure 1. The retinal vessel reactivity and time course components used in SDRA Figure adapted with 
consent from author. The copyright of the original image rests with the Association for Research in Vision and 
Ophthalmology19.
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no statistically significant differences between the two groups with regards to age and gender distribution of the 
participants (p > 0.05).
The anthropometric characteristics of the normal and overweight group are also presented in Table 1. 
Compared to lean individuals, overweight subjects showed significantly greater right and left c-IMT (p = 0.005 
and p = 0.002, respectively), 24-hr BP values (SBP, DBP, MBP, all p < 0.001), fasting glucose (p = 0.008) and TG 
(p = 0.003) levels, alongside higher TG: HDL-C ratio (p = 0.010). In addition, overweight individuals exhibited 
higher body composition indices (weight, BMI, WHR, PBF, fat mass, all p < 0.001) and plasma levels of vWF 
(p = 0.01) than the age-matched controls.
Microvascular function. A multiple regression analysis found that weight and BMI had a positive effect on 
retinal arterial MD (b = 0.203; p = 0.017, and b = 0.190; p = 0.025, respectively), but not on the other measured 
microvascular parameters.
The measured retinal parameters presented in Table 2 indicate that, after correcting for all influential variables 
(BMI, BP), overweight individuals exhibited a reduced arterial MD (p = 0.039) and bFR (p = 0.022), as well as, an 
increased MDRT (p = 0.047) compared to the lean subjects. There were no differences in retinal venous reaction 
parameters between the two study groups (all p > 0.05).
Macrovascular function. The brachial artery results presented in Table 3 show that after correcting for 
influential variables (BMI, BP), the baseline vessel diameter was larger in the overweight individuals when com-
pared to the age- and gender matched lean controls (p = 0.018). All the other measured brachial parameters were, 
however, comparable between the two groups (p > 0.05).
Mean (SD)
p-value
Control group 
[n = 50]
Overweight Group 
[n = 50]
Demographic Data
 Age (years) 41.7 (11.1) 42.2 (10.6)
 SBP (mmHg) 114 (14) 123 (12)* < 0.001
 DBP (mmHg) 72 (10) 81 (9)* 0.001
 MAP (mmHg) 86 (10) 92 (9)* < 0.001
 IOP (mmHg) 13 (3) 14 ± (2) 0.411
Bodycomposition Data
 Weight (kg) 65.4 (9.4) 78.5 (9.3)* <0.001
 BMI (kg/m2) 22.4 (3.1) 27.4 (1.3)* <0.001
 WHR (AU) 0.90 (0.14) 0.95 (0.03)* <0.001
 PBF (%) 25.8 (7.1) 32.1 (7.6)* <0.001
 Fat Mass (kg) 16.8 (5.3) 24.8 (4.7)* <0.001
 Fat Free Mass (kg) 48.7 (9.2) 53.7 (10.7)* <0.001
Metabolic Data
 Glucose (mmol/L) 4.78 (0.75) 5.12 (0.64)* 0.008
 2 hour GTT (mmol/L) 6.67 (2.29) 7.33 (2.14) 0.146
 TG (mmol/L) 1.08 (0.41) 1.42 (0.79)* 0.003
 HDL Cholesterol (mmol/L) 1.27 (0.41) 1.14 (0.38) 0.065
 LDL Cholesterol (mmol/L) 2.53 (0.79) 2.74 (0.88) 0.142
 Total Cholesterol (mmol/L) 4.30 (0.83) 4.53 (0.97) 0.142
 TG: HDL-C (mmol/L) 2.36 (2.06) 3.37 (2.95)* 0.01
CVD Risk Data
 R-IMT (mm) 0.052 (0.015) 0.058 (0.014) 0.005
 L-IMT (mm) 0.053 (0.016) 0.064 (0.015)* 0.002
 Framingham Score (%) 1.7 (2.4) 2.1 (3.4) 0.479
 Total: HDL-C (mmol/L) 3.70 (1.32) 4.36 (1.57)* 0.01
Biochemical Data
 vWF (μ /dL) 112.37 (58.67) 141.24 (55.36)* 0.01
Table 1.  Baseline data for lean and overweight groups. Values quoted in mean ± SD. SBP: systolic blood 
pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; IOP: intraocular pressure; BMI: body 
mass index; WHR: waist-to-hip ratio; PBF: percentage body fat; GTT: glucose tolerance test; TG: triglyceride; 
HDL: high-density lipoprotein; LDL: low-density lipoprotein; TG: HDL-C: TG-to-HDL ratio; CVD: 
cardiovascular disease; R-IMT: right intima media thickness L-IMT: left intima media thickness; vWF: von 
Willebrand factor. *Significant differences when compared to normal weight controls (p < 0.01).
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Discussion
This study demonstrates, for the first time, that otherwise healthy overweight individuals present with signs of 
microvascular functional impairment, as well as, increased circulatory plasma markers of endothelial dysfunc-
tion when compared to lean individuals. Although presenting with a larger baseline diameter, the brachial artery 
function was not affected in our overweight individuals cohort.
Consistent with previous research21, the present study demonstrates that overweight subjects show elevated 
BP values, higher TG, cholesterol, and fasting blood glucose. All these factors either separate or in conjunction, 
are well known contributors to cardiovascular risk and pre-diabetes in both adults and children7,21. In particular, 
triglyceride-rich lipoprotein remnants may cause endothelial damage22. In addition, the TG: HDL-C ratio was 
also increased in our overweight subjects and this parameter is a known independent determinant of increased 
arterial stiffness23. An elevated TG: HDL-C ratio has also been shown to have a strong correlation with fasting 
plasma insulin concentrations and when used alongside TG levels, represents a good surrogate marker for the 
presence of insulin resistance (IR)24. It is known that abnormal IR plays an important role in the development of 
endothelial dysfunction through a reduced production of NO, as well as, by accelerating the onset of atheroscle-
rosis25. Indeed, our overweight cohort demonstrated signs of pre-clinical atherosclerotic changes as measured 
by c-IMT and a modified baseline diameter of the brachiar artery, as measured by FMD; some of these param-
eters are well-known predictors for future cardiovascular complications26–28. However, we have not observed 
any correlation between c-IMT and FMD changes and this could further support previous assumptions that in 
younger patients without overt disease, but with certain risk for cardiovascular pathologies, there is no direct 
relationship between functional (FMD) and structural(c-ITM) vascular modifications29. Indeed, vascular dys-
function is known to precede the occurrence of atherosclerosis and signals the risk for future vascular disease30. 
Our overweight group also demonstrated abnormal vWF levels, possibly showing pathophysiological changes of 
the vascular endothelium. Nevertheless, neither of the measured macrovascular parameters correlated with this 
circulatory parameter.
An important finding of the present study was the detection of an impaired retinal vessel function in response 
to flickering stimulus (a reduced bFR and arterial MD and an increased MDRT) in overweight but not in lean 
individuals. It has been previously reported that a high BMI can be associated with narrower retinal arteriolar 
calibres31,32. In addition, complex alterations of the retinal microvascular function were already observed in obese 
individuals of various age groups11,33. Nevertheless, to our knowledge, this is the first report showing functional 
retinal vascular changes in overweight but not yet obese individuals, therefore, opening a new opportunity for early 
detection and prevention of cardiovascular complication in this type of population. Although the precise mech-
anisms behind our results need further elucidation we can, however, formulate some hypotheses. For instance, 
there is evidence to suggest that the changes observed in our measured MD and MDRT parameters could be 
the result of either early atherosclerosis, increased arterial stiffness, or reduced NO bioavailability to peripheral 
tissues34. Indeed, a high BMI has been found to be associated with reduced NO5 and increased levels of vaso-
constrictor substances such as endothelin-1 (ET-1) and angiotensin-II (Ang-II)35. Therefore, our observation 
Mean (SD)
p-valueControl group [n = 50] Overweight Group [n = 50]
Artery
 AD (AU) 121.59 (112.40–132.60) 120.96 (109.19–131.22) 0.09
 BDF (AU) 5.71 (3.75–7.09) 5.04 (2.77–6.67) 0.129
 MD (%) 5.55 (3.66–7.12) 4.54 (2.80–5.98)* 0.039
 MDRT (secs) 16.9 (12.3–20.7) 20.5 (14.0–24.0)* 0.047
 MC (%) 3.24 (1.66–4.57) 3.14(1.58–4.59) 0.526
 MCRT (secs) 19.7 (17.3–23.3) 20.3 (17.2–23.2) 0.222
 DA (AU) 8.78 (6.78–10.18) 7.68 (5.24–9.00) 0.053
 bFR (%) 3.76 (1.02–4.83) 2.12 (0.43–4.05)* 0.022
Vein
 AD (AU) 156.73 (139.18–173.78) 156.00 (142.47–166.35) 0.471
 BDF (AU) 4.13 (2.56–5.12) 4.29 (2.68–5.31) 0.461
 MD (%) 5.59 (4.44–6.54) 5.64 (3.87–6.71) 0.433
 MDRT (secs) 20.1 (17.3–22.7) 19.9 (17.0–23.2) 0.789
 MC (%) 1.44 (0.33–4.84) 1.75 (0.63–2.16) 0.665
 MCRT (secs) 21.8 (19.7–25.3) 21.1 (18.6–23.7) 0.525
 DA (AU) 7.27 (5.33–9.00) 7.39 (4.83–9.31) 0.323
 bFR (%) 3.12 (1.74–4.40) 3.16 (1.13–4.91) 0.425
Table 2.  Retinal arterial and venous measures for both groups. Average values corrected for CVD risk 
markers quoted in mean (IQR). AU: arbitrary units; AD: absolute diameter; BDF: baseline diameter fluctuation; 
MD: maximum dilation; MDRT: reaction time to reach maximum diameter to flicker stimulation; MC: 
maximum constriction; MCRT: reaction time to maximum constriction post flicker; DA: dilation amplitude; 
bFR: baseline-corrected flicker response. *Significant values in bold (p < 0.05, ANCOVA).
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showing that both weight and BMI had significant influences on retinal arterial MD parameters could possibly be 
explained by the detrimental effect of BMI on the vascular dilatory capacity of the retinal microvessels through 
the above mentioned mechanisms. Although neither NO or vasoconstrictor substances were measured in the 
present study, one could hypothesize that abnormal levels of vasodilatory or vasoconstrictory mediators are, at 
least in part, responsible for our findings. More research is necessary to confirm our hypothesis.
Despite recording a modified baseline diameter of the brachial artery, we could not demonstrate any signs 
of macrovascular dysfunction in our overweight cohort. The literature reports conflicting results on the effect 
of overweight abd obesity on macrovascular function6,36–38. It is possible that the vascular effect of the adi-
pokines secrated by the perivascular adipose tissue (PVAT) at this level varies according to the degree of obe-
sity39. Moreover, in physiological conditions, the PVAT can also have a vasorelaxant effect with a protective role40. 
This effect could have been responsible for our finding of an increased brachial artery baseline diameter in our 
overweight individuals it which PVAT was not yet dysfunctional enough to exert detrimental effects on the mac-
rovascular function41. Nevertheless, the macro- and microvascular beds’ functions are governed by different phys-
iological mechanisms. Moreover, it is the microcirculation that may be a better target for the assessment of risk as 
it is the microvessels that are considered to be the first to be affected in the course of vascular disease9. Therefore, 
our finding of abnormal vascular function at the retinal microvascular level in overweight individuals without 
any overt diseases is relevant and points towards the need for a much earlier screening for vascular detrimental 
effects that any excess adiposity could have.
As discussed above, microvascular dysfunction can be trigerred in areas with PVAT by subclinical inflam-
mation mediated via adipokines/cytokines and infiltrating macropahges42. Nevertheless, these molecules can 
also trigger remote inflammatory effects withy potential vascular changes as far as the retinal circulation, usually 
devoided of PVAT, therefore, resulting in abnormal vascular function at this level43. Further research is necessary 
to elucidate this point.
Dietary and social factors (such as ingestion of high saturated fats or lack of exercise) have not been assessed 
in the present study and this could therefore be perceived as a limitation. Moreover, larger studies are needed 
to investigate the effect of other possible confounding factors such as insulin sensitivity and menopause status. 
Nevertheless, even in the presence of these limitations, the results of our study show that in overweight but not 
yet obese individuals, signs of microvascular dysfunction exist alongside with abnormal circulatory levels of 
cardiovascular risk markers. We suggest that the assessment of retinal microcirculation may be a good, easy and 
non-invasive alternative for assessing vascular dysfunction associated with excess adiposity44. Therefore, the clin-
ical relevance of screening for early CVD risk in overweight individuals using this method is supported by these 
preliminary, but promising results.
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